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Tokyo 162-8480, Japan.A2A adenosine receptor (A2AR), P2Y1 receptor (P2Y1R) and P2Y12 receptor (P2Y12R) are predominantly
expressedonhumanplatelets. The individual roleof eachof these receptors inplatelet aggregationhas
been actively reported. Previously, hetero-oligomerization between these three receptors has been
shown to occur. Here, we show that Ca2+ signaling evoked by the P2Y1R agonist, 2-methylthioladeno-
sine 50 diphosphate (2MeSADP) was signiﬁcantly inhibited by the A2AR antagonist (ZM241385 (4-(2-
[7-amino-2-(2-furyl)[1,2,4]-triazolo[2,3-a][1,3,5]triazin-5-yl amino]ethyl) phenol) and SCH442416)
and the P2Y12R antagonist (ARC69931MX (N
6-(2-methyl-thioethyl)-2-(3,3,3-triﬂuoropropylthio)-b,
c-dichloromethylene-ATP)) using HEK293T cells (human embryonic kidney) expressing the three
receptors. It was conﬁrmed that inhibition of P2Y1R signaling by A2AR and P2Y12R antagonists was
indeed mediated through A2AR and P2Y12R using 1321N1 human astrocytoma cells which do not
express P2Y receptors.Weexpect that intermolecular signal transduction and speciﬁc conformational
changes occur among components of hetero-oligomers formed by these three receptors.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
ADP is a physiologically important mediator, released from
damaged cells, which can lead to platelet aggregation. Various
receptors are involved in the complex process of platelet aggrega-
tion. Three purinergic receptor subtypes, A2AR (A2A adenosine
receptor), P2Y1R (P2Y1 receptor) and P2Y12R (P2Y12 receptor) are
thought to play individual roles in this process. ADP mediates
platelet activity by binding to P2Y1R and P2Y12R, with these recep-
tors sequentially acting in concert to achieve complete platelet
aggregation [1]. The P2Y1R couples to Gq/11, leading to subsequentchemical Societies. Published by E
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ethylene-ATP; HA, hemag
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i).
acology, School of Advanced
Wakamatsu-cho, Shinjuku-ku,activation of phospholipase C and an increase in cytosolic Ca2+ lev-
els [2]. P2Y1R additionally activates p160 Rho kinase, which is
responsible for morphological changes in platelets in response to
ADP [3]. Studies using P2Y1R knockout mice proved that this recep-
tor is absolutely required for both the ADP-induced rise in intracel-
lular calcium and morphological responses, as selective inhibition
of P2Y1R results in the abolition of these responses [2–4]. P2Y12R
is mostly involved in platelet aggregation upon binding of ADP
through activation of transduction pathways downstream of Gi/o,
including phosphoinositide 3-kinases, rap-1b, and vasodilator-
stimulated phosphoprotein dephosphorylation [5,6]. A2AR stimu-
lates Gs-coupled adenylate cyclase in platelets upon binding of
adenosine, and enhances the intracellular cAMP levels, a potent
molecule that inhibits platelet activation [7,8].
P2Y12R has been reported to positively regulate P2Y1R activity,
whereas P2Y1R negatively regulates P2Y12R activity [9]. In addi-
tion, formation of a heteromeric complex formed with these three
receptors has been demonstrated using co-immunoprecipitation
techniques in HEK293T cells (human embryonic kidney) co-
expressing these three receptors [10]. A2AR/P2Y1R and A2AR/
P2Y12R complexes were also present in human platelet mem-
branes, as seen via co-immunoprecipitation [10], supporting the
possibility of the formation of A2AR/P2Y1R/P2Y12R heteromeric
complexes in platelets. These observations suggest that direct
interactions among purinergic receptors in platelets may be in-
volved in physiological platelet aggregation and may provide alsevier B.V. All rights reserved.
Fig. 1. Mobilization of Ca2+ evoked by 2MeSADP pre-stimulated with various ligands. Fura 2-loaded HEK293T cells (non-transfected) were preincubated for 1 min with either
vehicle as control (A), 10 lM MRS2179 (B), 10 lM CGS21680 (C), 10 lM ZM241385 (D) or 10 lM ARC69931MX (E) as indicated. Cells were then stimulated with 1 lM
2MeSADP (arrow) and ﬂuorescence intensity was measured. Traces shown are representative of at least three separate experiments.
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Fig. 2. Mean peak of Ca2+ responses evoked by 2MeSADP pre-stimulated with various ligands. Differences between maximum and minimum cytosolic Ca2+ concentration in
response to 1 lM 2MeSADP pretreated with indicated reagents (10 lM) in HEK293T cells transfected with A2AR (A), P2Y12R (B), A2AR and P2Y12R (C) and in non-transfected
HEK293T (D). Results were expressed as percentage of control (pre-treated with vehicle), and show the mean of three independent experiments. ⁄P < 0.05 and ⁄⁄P < 0.01 vs.
vehicle by Dunnett’s test. MRS, 10 lM MRS2179; CGS, 10 lM CGS21680; ZM, 10 lM ZM241385; ARC, 10 lM ARC69931MX; ZM+ARC, 10 lM ZM241385+10 lM
ARC69931MX; SCH, 10 lM SCH442416.
T. Suzuki et al. / FEBS Letters 585 (2011) 3978–3984 3979means by which to maintain the delicate balance between resting
and activated platelet states.To explore further functional correlation of these receptors, we
examined signal transduction underlying P2Y1R in the presence of
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Fig. 3. Mean peak of Ca2+ responses evoked by 2MeSADP pre-stimulated with various concentrations of ZM241385 and ARC69931MX. Assays were performed in non-
transfected HEK293T cells pre-treated with ZM241385 (A) and ARC69931MX (B).
Fig. 4. Effect of PTX treatment on [Ca2+]i elevation induced by 1 lM 2MeSADP. Non-transfected HEK293T cells treated with 100 ng/ml PTX for 16 h were used in this assay.
Traces shown are representative of at least three separate experiments pre-treated with vehicle (A) and 10 lM ARC69931MX (B). (C) Mean values of maximal peak responses
of (A) and (C) expressed as percentage control (pre-treated with vehicle) are representative of three independent experiments.
3980 T. Suzuki et al. / FEBS Letters 585 (2011) 3978–3984A2AR and P2Y12R ligands in HEK293T cells expressing the three
receptors.
2. Materials and methods
2.1. cDNA constructs and cell transfection
pCDNA3.1-3HA tagged human A2AR was purchased from Mis-
souri S&T cDNA Resource Center (Rolla, MO). pCDNA3-Myc-tagged
P2Y1R was constructed as described previously [11]. pMSF1-Flag
tagged human P2Y12R was provided kindly from Dr. M. Kikyo at
Mitsubishi Tanabe Pharma Corporation. HEK293T cells were main-
tained and were transfected using FuGENE HD (Roche Applied Bio-
science, Manheim, Germany) as previously outlined [12]. 1321N1
human astrocytoma cells were cultured in DMEM supplemented
with 10% fetal calf serum, 100 U/ml penicillin G and 100 lg/ml
streptomycin. 1321N1 cells were transfected using electropora-
tion. A total of 1  106 cells were mixed with 6 lg of the plasmidDNA mixture and kept in 2-mm electroporation cuvettes (BEX, To-
kyo, Japan). Cell transfection was then induced by a pulse of 300V
and 75 lF with no shunt resistor using a CelljecT Duo (Thermo
Hybaid, Franklin, MA). After electrical stimulus, cells were trans-
ferred into a 150 mm-dish for culture.
2.2. Measurement of intracellular Ca2+ concentrations
Changes in intracellular free Ca2+ concentration ([Ca2+]i) were
monitored by the intensity of fura 2 ﬂuorescence at 37C using
a spectroﬂuorometer (FP-6500; Hitachi, Osaka, Japan), as de-
scribed previously [13]. Cells were washed twice with Tyrode’s
solution (137 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 1.8 mM
CaCl2, 20 mM HEPES, and 5.6 mM glucose, pH 7.4). After centrifu-
gation at 250 g for 2 min, cells were treated with fura 2-AM (1
lM; Dojindo Laboratories, Kumamoto, Japan) at 37C for 15
min. Cells were then centrifuged at 250 g for 2 min and washed
twice with Tyrode’s buffer. The cells were suspended in modiﬁed
Fig. 5. Endogenous expression of A2AR, P2Y1R and P2Y12R in 1321N1 and HEK293T cells. (A) Fura 2-loaded 1321N1 cells (non-transfected) were stimulated with 1 lM
2MeSADP (arrow) and ﬂuorescence intensity was measured. Traces shown are representative of at least three separate experiments. cAMP accumulation in non-transfected
1321N1 (B, C) and HEK293T cells (D, E). Results were normalized against the cAMP concentration in vehicle-treated cells. The results are means of more than two independent
experiments performed in triplicate. ⁄P < 0.01 vs. vehicle and #P < 0.01 vs. FSK-evoked cAMP concentration by Dunnett’s test.
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mM CaCl2, 20 mM HEPES, and 5.6 mM glucose, pH 7.4) at a den-
sity of 2  105 cells/ml, and 1.5 ml of the cell suspension was
used for fura 2 assays. Fura 2 ﬂuorescence, at 510 nm, was mon-
itored every second with excitation wavelength at 340 and 380
nm.
2.3. Measurement of intracellular cAMP concentrations
Intact HEK293T and 1321N1 cells were plated on 48-well plates
coated with poly-L-lysine (0.1 mg/ml) at 4  104 cells/well and5  104 cells/well, respectively, and cultured for 24 h. Next, the
cells were incubated in pre-warmed HEPES–EMEM for 15 min at
37 C and then further incubated for 15 min at 37 C in HEPES–
EMEM containing 100 lM of Ro-20-1724, with or without a recep-
tor antagonist (10 lM). The cells were then stimulated with a
receptor agonist (1 lM) and FSK (forskolin) (100 lM for 1321N1
cells and 50 lM for HEK293T cells), and incubated for another
10 min. Reactions were terminated by adding 2.5% perchloric acid.
Acid-extracts were mixed with a 1/10 volume of 4.2 N KOH to neu-
tralize the acid, forming potassium perchlorate as a precipitate.
Cyclic AMP in the supernatant was succinylated and measured
3982 T. Suzuki et al. / FEBS Letters 585 (2011) 3978–3984using a radioimmunoassay kit (Yamasa, Tokyo, Japan) according to
the manufacturer’s protocol.
3. Results and discussion
3.1. Intracellular Ca2+ mobilization evoked by P2Y1R stimulation was
attenuated by ZM241385 and ARC69931MX
We examined the effect of ligands for A2AR and P2Y12R on the
mobilization of intracellular Ca2+ as a key index of P2Y1R-mediated
signaling. These observations were performed using non-transfec-
ted HEK293T cells which endogenously express A2AR, P2Y1R and
P2Y12R [14,15]. As expected, stimulation of the P2Y1R with 2Me-
SADP (2-methylthiol-ADP), an agonist of P2Y1R and P2Y12R, caused
an increase in Ca2+ release (Fig. 1A), which was absolutely blocked
by pre-treatment with MRS2179 (N6-methyl-20-deoxyadenosine-
30,50-bisphosphate), a P2Y1R speciﬁc antagonist (Fig. 1B). These
ﬁndings indicated that normal P2Y1R signaling via Gq/11 in non-
transfected HEK293T cells existed. Pre-treatment with CGS21680
(3-[4-[2-[ [6-amino-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihy-
droxy-oxolan-2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid),
an A2AR speciﬁc agonist, did not affect Ca2+ mobilization induced by
2MeSADP (Fig. 1C). By contrast, treatment with ZM241385 (4-(2-
[7-amino-2-(2-furyl)[1,2,4]-triazolo[2,3-a][1,3,5]triazin-5-yl amino]
ethyl) phenol) and ARC69931MX (N6-(2-methyl-thioethyl)-2-
(3,3,3-triﬂuoropropylthio)-b,c-dichloromethylene-ATP), which are
speciﬁc antagonists for A2AR and P2Y12R respectively, caused
decreased Ca2+ release (Fig. 1D, E). ZM241385 is also known to be
antagonist or inverse agonist for A2B receptor [16,17], and HEK293
cells endogenously express A2B receptor [18,19]. Then we tested if
the above inhibitory effect of ZM241385 on Ca2+ mobilization in-
duced by 2MeSADP was via either A2AR or A2BR using SCH442416,
which shows selective afﬁnity for A2AR whereas has little activity0 25 50 75 100 125 150
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Fig. 6. Mobilization of Ca2+ evoked by 2MeSADP in 1321N1 cells transfected with P2
preincubated for 1 min with either vehicle as control (A), 10 lM ZM241385 (B), or 10 l
(arrow) and ﬂuorescence intensity was measured. Traces shown are representative of at l
C) expressed as percentage control (pre-treated with vehicle) are representative of threfor A2BR [20]. As shown in Fig. 2D, similar effect to ZM241385 was
obtained, suggesting inhibitory effect of ZM241385 on Ca2+ mobili-
zation induced by 2MeSADP was via either A2AR rather than A2BR.
Similar results were obtained with HEK293T cells transfected
with A2AR and/or P2Y12R (Fig. 2). Because an inhibition of Ca2+ in-
crease did not facilitated following the overexpression of A2AR and
P2Y12R, it is possible that endogenous A2AR and P2Y12R are sufﬁcient
in affecting Ca2+ mobilization through endogenous P2Y1R. Simulta-
neous treatmentwith ZM241385andARC69931MXcaused additive
(Fig. 2A-C, ZM+ARC) or similar effects (Fig. 2D, ZM+ARC) to stimula-
tionwithZM241385orARC69931MXalone. Thisdecreasewasdose-
dependent, with an estimated IC50 of 6.64 and 1.16 lM for
ZM241385 (Fig. 3A) and ARC69931MX (Fig. 3B), respectively. The
difference in IC50 values indicates that ZM241385andARC69931MX
effect P2Y1R with different potency or via different mechanisms.
To test whether the decrease in Ca2+ in the presence of
ARC69931MX was due to an antagonistic effect on 2MeSADP-stim-
ulated P2Y12R, we measured Ca2+ mobilization using cells treated
with PTX (pertussis toxin) to block signal transduction via Gi/o
(Fig. 4). By contrast to PTX-untreated cells (Figs. 1 and 2), Ca2+ in-
crease was comparable between negative control (vehicle-treated)
and ARC69931MX-treated cells (Fig. 4). These results indicate that
signal transduction following binding of 2MeSADP or endogenous
ADP to P2Y12R is indeed involved with the inhibition of P2Y1R-
evoked Ca2+ increase by ARC69931MX, which may not be due to
direct blockage of P2Y1R by ARC69931MX.
3.1.1. 1321N1 cells endogenously express A2AR, but not P2Y1R and
P2Y12R
For further conﬁrmation of this mechanism, we looked for cul-
tured cells which did not express the above three receptors.
1321N1 cells do not express P2Y1R and P2Y12R [21,22], but their
expression of A2AR is unknown. We examined endogenous0 25 50 75 100 125
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)
Y1R. Fura 2 was loaded in 1321N1 cells transfected with P2Y1R, and cells were
M ARC69931MX (C) as indicated. Cells were then stimulated with 1 lM 2MeSADP
east three separate experiments. (D) Mean values of maximal peak responses of (A–
e independent experiments. ⁄P < 0.05 vs. vehicle by Dunnett’s test.
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responsiveness as an index of intracellular Ca2+ and intracellular
cAMP levels (Fig. 5). Intracellular Ca2+ was not elevated by 1 lM
2MeSADP (Fig. 5B), conﬁrming previous ﬁndings concerning the ab-
sence of P2Y1R in 1321N1 cells. Results obtained via immunoblot-
ting, using anti-A2AR, suggested expression of endogenous A2AR in
non-transfected HEK293T cells and also in non-transfected
1321N1 cells (data not shown). To conﬁrm these results, we mea-
sured intracellular cAMP accumulation elevated via agonistic stim-
ulation of A2AR which couples to Gs. CGS21680 (1 lM) promoted
cAMP accumulation both in non-transfected 1321N1 (Fig. 5B) and
non-transfected HEK293T cells (Fig. 5C). This elevationwas blocked
by pre-treatment with 10 lM ZM241385, indicating the expression
of endogenousA2AR both inHEK293T and1321N1 cells. Next,we as-
sessed the endogenous expression of P2Y12R, which couples to Gi/o,
by observing a decrease in intracellular cAMP evoked by FSK upon
stimulation of P2Y12R with 2MeSADP. 2MeSADP (1 lM) decreased
FSK-evoked cAMP generation in HEK293T cells (Fig. 5E), but not in
1321N1 cells (Fig. 5C). This inhibitory effect of 2MeSADPwas totally
reversed by pre-treatment with 10 lM ARC69931MX in HEK293T
cells (Fig. 5E). Taken together, these results suggest that endogenous
A2AR was expressed both in HEK293T and 1321N1 cells, whereas
endogenous P2Y1R and P2Y12R were expressed in HEK293T cells
but not in 1321N1 cells.
3.2. Involvement of P2Y12R in attenuation of 2MeSADP-evoked Ca
2+
increase by ARC69931MX was conﬁrmed using 1321N1 cells
Finally, we tested whether attenuation of P2Y1R-evoked Ca2+ in-
crease by ZM241385 and ARC69931MX, shown in Fig. 1, occurred
in 1321N1 cells which express endogenous A2AR but not P2Y12R (as
conﬁrmed above). Because 1321N1 cells do not express endoge-
nous P2Y1R (Fig. 5A and reference [21]), the cells were transfected
with P2Y1R and used for further experiments. As transfection efﬁ-
ciency in 1321N1 cells was too low to perform a Ca2+ assay using
transfection reagents such as FuGENE HD and Lipofectamine2000
(Invitrogen, Carlsbad, CA; data not shown), we used electropora-
tion to improve efﬁciency. In 1321N1 cells transfected with
P2Y1R, intracellular Ca2+ increase by 2MeSADP was attenuated
with ZM241385 (Fig. 6A, C), as seen in HEK293T cells, but was
comparable to negative control (vehicle) in ARC69931MX-treated
1321N1 cells (Fig. 6B, C). These results suggest that attenuation
of P2Y1R-evoked Ca2+ signaling with ARC69931MX was indeed
through P2Y12R, and not due to direct inhibition to P2Y1R.
4. Conclusion
In the present study, we focused on the functional correlation
among purinergic receptors. Using HEK293T cells endogenously
expressing A2AR, P2Y1R and P2Y12R, negative regulation of P2Y1R
function by A2AR and P2Y12R speciﬁc antagonists was shown. This
inhibition of P2Y1R-evoked Ca2+ signaling by a P2Y12R antagonist
was revealed to be through P2Y12R, and conﬁrmed by Ca2+ assay
using PTX-treated HEK293T cells and 1321N1 cells transfected
with P2Y1R, which do not express endogenous P2Y12R.
Based on these results, an additional molecular mechanism of
action of ARC69931MX, which has been clinically used for an anti-
platelet drug as ‘Cangrelor’ [22], beyond the direct blockage of
P2Y12R, was proposed. It is possible that this drug exert pharmaco-
logical action not only via P2Y12R but also via P2Y1R. A2AR has been
known to inhibit platelet activation through accumulation of the
intracellular cAMP levels [7,8]. Interestingly, according to the pres-
ent results, blocking of A2AR by ZM241385 was suggested to cause
two different effects, i.e. facilitation of platelet aggregation by
blocking of A2AR, and inhibition of platelet aggregation and platelet
shape changes via attenuation of P2Y1R function.Formation of a heteromeric complex containing these three
receptors was seen in HEK293T cells co-transfected with the three
receptors [10]. Though further exploration is necessary, it is ex-
pected that intermolecular signal transduction and speciﬁc struc-
tural changes occur among components of the hetero-oligomer
composed of these receptors.
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